Alopecia and Semaglutide: Connecting the Dots for Patient Safety

Emerging evidence suggests a potential link between semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight loss, and alopecia. Studies, including a retrospective cohort study and a scoping review, indicate an increased incidence of hair loss associated with semaglutide use. The rapid weight loss from semaglutide may lead to nutritional deficiencies and endocrine disruptions, contributing to hair loss. While current evidence is largely observational, there is a call for comprehensive clinical trials to confirm this association and explore mechanisms. Addressing the psychosocial impact of alopecia is also crucial for patient care.